RxDoctor Payments Data

Atif Khan, MD

Radiation Oncology · New Brunswick, NJNPI 1255545653

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $1,457 of the $2,011 with a category attached, or 72.5%. Accuray Incorporated accounts for 95.8% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2022 at $1,927 and has fallen 98.7% since, to $25 in 2025.

$2,011in general payments, 2019–2025

Across 14 payments — averaging $143.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Accuray Incorporated$2K
  • Bristol Myers Squibb$59
  • Beone Medicines USA, Inc.$25
$4,676,355in research payments, 2019–2025

Across 18 payments — averaging $259,798 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$4.2M
  • Clovis Oncology, Inc.$345K
  • Siemens Medical Solutions USA, Inc.$164K

What the payments were for

  • Speaking & faculty fees$724%
  • Travel & lodging$1,45772%
  • Food & beverage$48124%

General payments by program year

20
22
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,011 in reported general payments places this provider in the 75th percentile of 132 radiation oncology providers in New Jersey.

See all radiation oncology providers in New Jersey

Medicare billing

Part B allowed, 2024
$108,634
Medicare patients
386
Services billed
1,129

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Triamcinolone Acetonide49$772

Paid to pharmacies, not to this prescriber.

Other radiation oncology in New Brunswick

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →